These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 36845983)
21. Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study. Robbins M; Haroz R; Mazzarelli A; Clements D; Jones CW; Salzman M J Subst Abuse Treat; 2021 Nov; 130():108405. PubMed ID: 34118697 [TBL] [Abstract][Full Text] [Related]
22. Changes in Buprenorphine Treatment After Medicaid Expansion. Olfson M; Zhang VS; King M; Mojtabai R Psychiatr Serv; 2021 Jun; 72(6):633-640. PubMed ID: 33730878 [TBL] [Abstract][Full Text] [Related]
23. Implications of county-level variation in U.S. opioid distribution. Griffith KN; Feyman Y; Auty SG; Crable EL; Levengood TW Drug Alcohol Depend; 2021 Feb; 219():108501. PubMed ID: 33421805 [TBL] [Abstract][Full Text] [Related]
24. States' implementation of the Affordable Care Act and the supply of physicians waivered to prescribe buprenorphine for opioid dependence. Knudsen HK; Lofwall MR; Havens JR; Walsh SL Drug Alcohol Depend; 2015 Dec; 157():36-43. PubMed ID: 26483356 [TBL] [Abstract][Full Text] [Related]
25. Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013. Burns RM; Pacula RL; Bauhoff S; Gordon AJ; Hendrikson H; Leslie DL; Stein BD Subst Abus; 2016; 37(1):63-9. PubMed ID: 26566761 [TBL] [Abstract][Full Text] [Related]
26. Impact Of Long-Term Buprenorphine Treatment On Adverse Health Care Outcomes In Medicaid. Samples H; Williams AR; Crystal S; Olfson M Health Aff (Millwood); 2020 May; 39(5):747-755. PubMed ID: 32364847 [TBL] [Abstract][Full Text] [Related]
27. Association between state Medicaid expansion status and naloxone prescription dispensing. Sohn M; Talbert JC; Delcher C; Hankosky ER; Lofwall MR; Freeman PR Health Serv Res; 2020 Apr; 55(2):239-248. PubMed ID: 32030751 [TBL] [Abstract][Full Text] [Related]
28. Demographic and Geospatial Analysis of Buprenorphine and Methadone Prescription Rates. Peterman NJ; Palsgaard P; Vashi A; Vashi T; Kaptur BD; Yeo E; Mccauley W Cureus; 2022 May; 14(5):e25477. PubMed ID: 35800815 [TBL] [Abstract][Full Text] [Related]
29. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States? Rhee TG; Rosenheck RA Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111 [TBL] [Abstract][Full Text] [Related]
30. State pain management clinic policies and county opioid prescribing: A fixed effects analysis. Frizzell LC; Vuolo M; Kelly BC Drug Alcohol Depend; 2020 Nov; 216():108239. PubMed ID: 32854001 [TBL] [Abstract][Full Text] [Related]
31. Estimating the impact on initiating medications for opioid use disorder of state policies expanding Medicaid and prohibiting substance use during pregnancy. Choi S; Stein MD; Raifman J; Rosenbloom D; Clark JA Drug Alcohol Depend; 2021 Dec; 229(Pt A):109162. PubMed ID: 34768053 [TBL] [Abstract][Full Text] [Related]
32. Patterns and Quality of Buprenorphine Opioid Agonist Treatment in a Large Medicaid Program. Gordon AJ; Lo-Ciganic WH; Cochran G; Gellad WF; Cathers T; Kelley D; Donohue JM J Addict Med; 2015; 9(6):470-7. PubMed ID: 26517324 [TBL] [Abstract][Full Text] [Related]
33. Development of an Emergency Department-Based Intervention to Expand Access to Medications for Opioid Use Disorder in a Medicaid Nonexpansion Setting: Protocol for Engagement and Community Collaboration. Walter LA; Li L; Rodgers JB; Hess JJ; Skains RM; Delaney MC; Booth J; Hess EP JMIR Res Protoc; 2021 Apr; 10(4):e18734. PubMed ID: 33913818 [TBL] [Abstract][Full Text] [Related]
34. Medications for opioid use disorder among pregnant women referred by criminal justice agencies before and after Medicaid expansion: A retrospective study of admissions to treatment centers in the United States. Winkelman TNA; Ford BR; Shlafer RJ; McWilliams A; Admon LK; Patrick SW PLoS Med; 2020 May; 17(5):e1003119. PubMed ID: 32421717 [TBL] [Abstract][Full Text] [Related]
35. Differences in medicaid expansion effects on buprenorphine treatment utilization by county rurality and income: A pharmacy data claims analysis from 2009-2018. Golan OK; Sheng F; Dick AW; Sorbero M; Whitaker DJ; Andraka-Christou B; Pigott T; Gordon AJ; Stein BD Drug Alcohol Depend Rep; 2023 Dec; 9():100193. PubMed ID: 37876376 [TBL] [Abstract][Full Text] [Related]
36. Medicaid prescription limits and their implications for naloxone accessibility. Roberts AW; Look KA; Trull G; Carpenter DM Drug Alcohol Depend; 2021 Jan; 218():108355. PubMed ID: 33309522 [TBL] [Abstract][Full Text] [Related]
37. Medicaid expansion and drug overdose mortality during the COVID-19 pandemic in the United States. Auty SG; Griffith KN Drug Alcohol Depend; 2022 Mar; 232():109340. PubMed ID: 35131533 [TBL] [Abstract][Full Text] [Related]
39. Medicaid managed care restrictions on medications for the treatment of opioid use disorder. Stewart MT; Andrews CM; Feltus SR; Hodgkin D; Horgan CM; Thomas CP; Nong T Health Serv Res; 2024 Oct; ():. PubMed ID: 39390740 [TBL] [Abstract][Full Text] [Related]
40. Chronic prescription opioid use predicts stabilization on buprenorphine for the treatment of opioid use disorder. Varisco T; Shen C; Thornton D J Subst Abuse Treat; 2020 Oct; 117():108073. PubMed ID: 32811630 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]